Does TyG-ABSI improve the assessment of cardiovascular disease and mortality risk compared to traditional indices in populations with metabolic syndrome?
TyG-ABSI may serve as a valuable novel index for risk stratification of cardiovascular disease and mortality in patients with metabolic syndrome.
Our study highlights the value of TyG-ABSI in assessing cardiovascular disease and mortality risk in populations with MetS, providing new evidence for medical practice and public health interventions.
Zheng et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: